Navigation Links
Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Date:10/3/2007

onically infected with HCV genotype 1. This adaptive Phase 1 study is comprised of three parts:

Part 1 is a single ascending dose study of R7128 conducted in 46 healthy volunteers. The primary objective of Part 1 is to assess the safety, tolerability and pharmacokinetics of R7128 following single ascending doses under fasting conditions. The secondary objective of Part 1 is to explore the effect of food on the pharmacokinetics of R7128. Results from the single ascending dose portion of the study indicated that all doses of R7128 studied (500 mg to 9000 mg) were generally safe and well-tolerated. All patients completed the study, and none experienced gastrointestinal adverse events or serious adverse events during the study. No hematological or laboratory abnormalities of clinical significance were noted.

Part 2 is a multiple ascending dose study of R7128 conducted in 40 patients chronically-infected with HCV genotype 1 who previously failed interferon therapy. The primary objective of Part 2 is to assess the safety, tolerability and pharmacokinetics of R7128 after once-daily (QD) or twice- daily (BID) dosing for 14 days. The secondary objective is to assess antiviral activity by measuring the change in HCV RNA. Preliminary data from the multiple ascending dose portion of the study indicated that R7128 demonstrated potent, dose-dependent antiviral activity in four patient cohorts receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. Patients receiving 1500 mg BID demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of viral rebound in any dose cohort during the 14 days of dosing. R7128 was generally safe and well tolerated. There were no serious adverse events, no adverse events requiring dose modification, no dose-related gastrointestinal adverse events and no clinically significant changes in hematologic or other laboratory parameters.

Part 3 is a multi-center, observ
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... , Chief Executive Officer, will be presenting at the 26 ... York Palace Hotel in New York . ... at 2:00 PM ET. In addition, Mr. Krakauer and ... for separate one-on-one meetings during the day. ...
(Date:11/21/2014)... -- Depomed, Inc. (NASDAQ: DEPO ) today announced that ... Annual Healthcare Conference in New York City . ... for 8:00 am EST (5:00 am PST) on Tuesday December 2, ... accessed via the Investor Relations page of the Depomed website at ... for 30 days on the company,s website. About ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2
... April 11, 2012  Blue Mountain Hospital has used an electronic ... announced plans to swap out its original technology with an ... "We were lucky to start out as a ... are using simply is not meeting all of our needs," ...
... BAY, Wis., April 11, 2012   IOD Incorporated™, ... health systems, and physician practices, today announced its response ... a proposed rule to delay ICD-10 from October 1, ... http://photos.prnewswire.com/prnh/20111207/CG18689LOGO ) According to HHS regulations ...
Cached Medicine Technology:Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 2Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 3IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 2IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 3
(Date:11/22/2014)... 23, 2014 BambooFlooringChina.com is a ... has proudly released its new collection of bamboo mats ... up to 29% off. , According to the ... tree-like grass, making it a highly renewable resource. Their bamboo ... a mixing color which comes from natural bamboo with caramel ...
(Date:11/22/2014)... York, NY (PRWEB) November 22, 2014 ... Therapeutics Goods Administration (TGA) approved it for use ... was approved and listed within the Therapeutic Goods ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione will ... a biotech specialist that sources and imports fine ...
(Date:11/22/2014)... 2014 Discount-Dress.com is an important ... firm is to increase the company’s online market share by ... selection of bridesmaid dresses and announced a bridesmaid dress promotion ... until Dec. 30, 2014. All the dresses from this company ... , In fact, Discount-Dress.com is very good at manufacturing wedding ...
(Date:11/22/2014)... TX (PRWEB) November 22, 2014 ... (ICS) as the complaint that the individual has ... for voiding. The report “Nocturia – Pipeline Review, ... development for Nocturia, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ...
(Date:11/22/2014)... York (PRWEB) November 22, 2014 A ... morcellators ( http://www.morcellatorlawsuit2015.com ) in minimally-invasive hysterectomies and ... signatures since the end of October, Bernstein Liebhard LLP ... the petition as of November 21st, 2014. That represents ... 86,042 supporters had signed on to the campaign.* , ...
Breaking Medicine News(10 mins):Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4
... than Alzheimer,s patients, healthy controls , , MONDAY, Oct. 13 ... than healthy people or Alzheimer,s patients to have vitamin ... of Medicine in Atlanta. , They compared vitamin D ... 99 healthy people matched for age and other factors. ...
... greater effect on women, study found , , MONDAY, Oct. 13 ... your brain shrinks, a new study has found. , ... you,re going to hurt your brain," said Rajesh Miranda, an ... A&M Health Science Center College of Medicine. "This is something ...
... AMERIGROUP Foundation,today announced a contribution in support of ... enhance the organization,s vocational,training program., SCHI is ... underprivileged children with special needs from,throughout New Jersey. ... suffering of the,most vulnerable members of the community. ...
... a Healthy Spine, PLANO, Texas, Oct. 13 ... Back Institute shares "Nine for Your Spine." The,release of ... October 16, 2008., National Spine Health Day was ... the most effective means of reducing the,prevalence and severity ...
... System, Supports Global Pharma Client in Closing ... CHESTER, Pa., Oct. 13 Modevity, LLC announced,today ... Imperium technology to become the primary platform for ... for their new product video content. Imperium is ...
... ANNAPOLIS, Md., Oct. 13 The National Coalition ... concerns over,the National CT Colonography Study published September ... evidence must be closely evaluated, and,patients need to ... risks. The National Coalition reminds patients that Colonoscopy,remains ...
Cached Medicine News:Health News:Parkinson's Patients More Prone to Vitamin D Deficiency 2Health News:Excess Drinking Shrinks the Brain 2Health News:AMERIGROUP Foundation Supports the School for Children with Hidden Intelligence 2Health News:Texas Back Institute Announces 'Nine for Your Spine' for National Spine Health Day - October 16 2Health News:Texas Back Institute Announces 'Nine for Your Spine' for National Spine Health Day - October 16 3Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3
... advancement in supralaryngeal airway management., ,The CobraPLA ... the hypopharynx where it abuts the structure of ... head design of the distal end of the ... epiglottis out of the way, facilitating ventilation through ...
Robertazzi Amber Latex Free Nasal Airways are manufactured from natural amber latex. Soft, flexible maximizing comfort....
Robertazzi Latex Free Nasal Airways are manufactured from soft neoprene and have smooth beveled tip for gentle insertion....
Extra soft for patient comfort., ,The Argyle® Nasopharyngeal Airway provides an open airway to make suctioning and bronchoscopy easier, safer, and less traumatic....
Medicine Products: